Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
13.31
-1.01 (-7.05%)
At close: Nov 15, 2024, 4:00 PM
13.50
+0.19 (1.43%)
After-hours: Nov 15, 2024, 5:40 PM EST
DAWN Employees
Day One Biopharmaceuticals had 155 employees as of December 31, 2023. The number of employees increased by 34 or 28.10% compared to the previous year.
Employees
155
Change (1Y)
34
Growth (1Y)
28.10%
Revenue / Employee
$657,761
Profits / Employee
-$543,826
Market Cap
1.34B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 155 | 34 | 28.10% |
| Dec 31, 2022 | 121 | 66 | 120.00% |
| Dec 31, 2021 | 55 | 35 | 175.00% |
| Dec 31, 2020 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| U.S. Physical Therapy | 6,720 |
| STAAR Surgical Company | 1,057 |
| MiMedx Group | 895 |
| Schrödinger | 867 |
| Rocket Pharmaceuticals | 268 |
| Syndax Pharmaceuticals | 184 |
| Praxis Precision Medicines | 82 |
| Cassava Sciences | 29 |
DAWN News
- 16 days ago - Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - GlobeNewsWire
- 4 weeks ago - Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 - GlobeNewsWire
- 3 months ago - Day One Reports Second Quarter 2024 Financial Results and Corporate Progress - GlobeNewsWire
- 3 months ago - Day One Announces Oversubscribed $175.0 Million Private Placement - GlobeNewsWire
- 4 months ago - Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor - GlobeNewsWire
- 5 months ago - Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers - GlobeNewsWire
- 6 months ago - Day One Announces Sale of Priority Review Voucher for $108 Million - GlobeNewsWire